不同调整剂量呋喹替尼在5 mg呋喹替尼三线治疗不耐受晚期结直肠癌患者中的应用效果  

Application effect of different adjusted doses of fruquintinib in advanced colorectal cancer patients with 5 mg fruquintinib third-line therapy intolerance

作　　者：薛磊[1] 赵馨萍 王留兴[1] XUE Lei;ZHAO Xinping;WANG Liuxing(Department of Medical Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,He’nan,China)

机构地区：[1]郑州大学第一附属医院肿瘤内科,郑州450052

出　　处：《癌症进展》2025年第1期33-35,62,共4页Oncology Progress

摘　　要：目的探讨不同调整剂量呋喹替尼在5 mg呋喹替尼三线治疗不耐受晚期结直肠癌患者中的应用效果。方法选取168例5 mg呋喹替尼三线治疗不耐受晚期结直肠癌患者,根据呋喹替尼调整剂量的不同分为低剂量组(n=83,调整剂量为3 mg)和高剂量组(n=85,调整剂量为4 mg)。比较两组患者的临床疗效、肿瘤标志物[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]水平、不良反应发生情况及随访1年生存率。结果高剂量组患者的疾病控制率为72.94%,高于低剂量组患者的57.83%,差异有统计学意义(P﹤0.05)。治疗后,两组患者CEA、CA19-9水平均低于本组治疗前,高剂量组患者CEA、CA19-9水平均低于低剂量组,差异均有统计学意义(P﹤0.05)。高剂量组患者的不良反应总发生率为7.06%,与低剂量组患者的4.82%比较,差异无统计学意义(P﹥0.05)。高剂量组患者的1年生存率为95.30%,高于低剂量组患者的84.30%,差异有统计学意义(P﹤0.05)。结论相比于3 mg调整剂量呋喹替尼,4 mg调整剂量呋喹替尼对5 mg呋喹替尼三线治疗不耐受晚期结直肠癌患者具有较好的临床疗效,能够降低血清肿瘤标志物水平,提高患者的生存率,且安全性较高。Objective To explore the application effect of different adjusted doses of fruquintinib in advanced colorectal cancer patients with 5 mg fruquintinib third-line therapy intolerance.Method A total of 168 advanced colorectal cancer patients with 5 mg fruquintinib third-line therapy intolerance were selected and divided into low-dose group(n=83,3 mg adjusted dose)and high-dose group(n=85,4 mg adjusted dose)according to the different adjusted doses of fruquintinib.The clinical efficacy,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)]levels,incidence of adverse reactions,and one year follow-up survival rate were compared between the two groups.Result The disease control rate in high-dose group was 72.94%,which was higher than 57.83% in low-dose group,and the difference was statistically significant(P<0.05).After treatment,the levels of CEA and CA19-9 in both groups were lower than those before treatment,the levels of CEA and CA19-9 in high-dose group were lower than those in low-dose group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in high-dose group was 7.06%,which was not statistically significant compared to 4.82% in low-dose group(P>0.05).The one-year survival rate in high-dose group was 95.30%,which was higher than 84.30% in low-dose group,and the difference was statistically significant(P<0.05).Conclusion Compared to 3 mg adjusted dose of fruquintinib,4 mg adjusted dose of fruquintinib has better clinical efficacy in advanced colorectal cancer patients with 5 mg fruquintinib third-line therapy intolerance.It can reduce serum tumor marker levels,improve survival rate,and has higher safety.

关 键 词：呋喹替尼 结直肠癌 调整剂量 临床疗效 安全性 

分 类 号：R735.3[医药卫生—肿瘤]